Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Evaluating Duchenne muscular dystrophy treatments with a 3D innervated skeletal muscle model
FY 2020-21
Summary
Motor neurons are cells that transmit electrical signals from the brain to skeletal muscle cells and evoke contractions that assist in human functions such as walking, swallowing and breathing. The position on muscle fibers where motor neurons attach is referred to as the neuromuscular junction. Although it is well accepted that neuromuscular junction activity is vital to skeletal muscle function and health, it is difficult to study the role of neuromuscular junction activity on healthy or diseased human skeletal muscle in part due to a lack of appropriate culture methods. To overcome this technical hurdle, we created and characterized a three-dimensional model of human skeletal muscle tissue containing motor neurons that can produce skeletal muscle cell contractions when treated with the biologically relevant stimuli. Furthermore, we miniaturized our innervated human skeletal muscle tissue platform allowing us to create many replicate tissues. Miniaturization is particularly important when performing research studies with precious human biopsy samples. In the current application, our goal is to use our pre-clinical tool to study the human neuromuscular junction in the context of the genetic disorder, Duchenne muscular dystrophy. Patients with Duchenne muscular dystrophy harbor a mutation in a gene that contains the instructions to produce a protein called dystrophin. Dystrophin is situated near the neuromuscular junction in skeletal muscle cells, but an involvement in regulating neuromuscular junction activity is not clear. The goal of our study is to uncover new roles of the neuromuscular junction in Duchenne muscular dystrophy disease progression and to evaluate the impact of clinically approved drugs that modify neuromuscular junction activity as a possible treatment for Duchenne muscular dystrophy patients.
Department
Program
Doctoral Research Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
439361
Name
Jacques Erik
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Musculoskeletal Health and Arthritis
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Evaluating Duchenne muscular dystrophy treatments with a 3D innervated skeletal muscle model
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Duchenne Muscular Dystrophy; Pre-Clinical Studies; Skeletal Muscle; Tissue Modeling
Abstract
Motor neurons are cells that transmit electrical signals from the brain to skeletal muscle cells and evoke contractions that assist in human functions such as walking, swallowing and breathing. The position on muscle fibers where motor neurons attach is referred to as the neuromuscular junction. Although it is well accepted that neuromuscular junction activity is vital to skeletal muscle function and health, it is difficult to study the role of neuromuscular junction activity on healthy or diseased human skeletal muscle in part due to a lack of appropriate culture methods. To overcome this technical hurdle, we created and characterized a three-dimensional model of human skeletal muscle tissue containing motor neurons that can produce skeletal muscle cell contractions when treated with the biologically relevant stimuli. Furthermore, we miniaturized our innervated human skeletal muscle tissue platform allowing us to create many replicate tissues. Miniaturization is particularly important when performing research studies with precious human biopsy samples. In the current application, our goal is to use our pre-clinical tool to study the human neuromuscular junction in the context of the genetic disorder, Duchenne muscular dystrophy. Patients with Duchenne muscular dystrophy harbor a mutation in a gene that contains the instructions to produce a protein called dystrophin. Dystrophin is situated near the neuromuscular junction in skeletal muscle cells, but an involvement in regulating neuromuscular junction activity is not clear. The goal of our study is to uncover new roles of the neuromuscular junction in Duchenne muscular dystrophy disease progression and to evaluate the impact of clinically approved drugs that modify neuromuscular junction activity as a possible treatment for Duchenne muscular dystrophy patients.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Jacques, Erik
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~